[1]
|
中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南(2018)[J]. 协和医学杂志, 2018, 9: 512-525. doi: 10.3969/j.issn.1674-9081.2018.06.007
Menopause Group, Obstertrics and Gynecology Branch, Chinese Medical Association. 2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J]. Xie He Yi Xue Za Zhi, 2018, 9: 512-525. doi: 10.3969/j.issn.1674-9081.2018.06.007 |
[2]
|
中华医学会妇产科学分会绝经学组. 早发性卵巢功能不全的激素补充治疗专家共识[J]. 中华妇产科杂志, 2016, 51: 881-886 doi: 10.3760/cma.j.issn.0529-567x.2016.12.001
Menopause Group, Obstertrics and Gynecology Branch, Chinese Medical Association. 2016 Consensus of hormone replacement therapy for premature ovarian insufficiency[J]. Zhonghua Fu Chan Ke Za Zhi, 2016, 51: 881-886. doi: 10.3760/cma.j.issn.0529-567x.2016.12.001 |
[3]
|
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288: 321-333. doi: 10.1001/jama.288.3.321 |
[4]
|
Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015, 1: 296-305. doi: 10.1001/jamaoncol.2015.0494 |
[5]
|
Crandall CJ, Hovey KM, Andrews C, et al. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women' s Health Initiative Observational Study[J]. Menopause, 2017, 24: 1145-1153. doi: 10.1097/GME.0000000000000899 |
[6]
|
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 289: 3243-3253. doi: 10.1001/jama.289.24.3243 |
[7]
|
Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J]. Br J Cancer, 2004, 91: 644-650. doi: 10.1038/sj.bjc.6601996 |
[8]
|
Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers[J]. JAMA Oncol, 2018, 4: 1059-1065. doi: 10.1001/jamaoncol.2018.0211 |
[9]
|
Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review[J]. Climacteric, 2018, 21: 111-122. doi: 10.1080/13697137.2017.1421925 |
[10]
|
Fait T. Menopause hormone therapy: latest developments and clinical practice[J]. Drugs Context, 2019, 8: 212551. |
[11]
|
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped[J]. Lancet, 2004, 363: 453-455. doi: 10.1016/S0140-6736(04)15493-7 |
[12]
|
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Natl Cancer Inst, 2005, 97: 533-535. doi: 10.1093/jnci/dji071 |
[13]
|
Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Natl Cancer Inst, 2008, 100: 475-482. doi: 10.1093/jnci/djn058 |
[14]
|
Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 years follow up of the Stockholm randomised trial[J]. Eur J Cancer, 2013, 49: 52-59. doi: 10.1016/j.ejca.2012.07.003 |
[15]
|
Marsden J, Marsh M, Rigg A. British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer[J]. Post Reprod Health, 2019, 25: 21-32. doi: 10.1177/2053369118824920 |
[16]
|
Sjögren LL, Mørch LS, Løkkegaard E. Hormone replace-ment therapy and the risk of endometrial cancer: a systematic review[J]. Maturitas, 2016, 91: 25-35. doi: 10.1016/j.maturitas.2016.05.013 |
[17]
|
Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J]. Am J Obstet Gynecol, 1996, 175: 1195-1200. doi: 10.1016/S0002-9378(96)70027-3 |
[18]
|
Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study[J]. Obstet Gynecol, 2001, 97: 555-560. |
[19]
|
Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer: a Gynecologic Oncology group study[J]. J Clin Oncol, 2006, 24: 587-592. doi: 10.1200/JCO.2005.02.8464 |
[20]
|
Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer: a Gynecologic Oncology group study[J]. Eur J Cancer, 2014, 50: 1628-1637. doi: 10.1016/j.ejca.2014.03.006 |
[21]
|
Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J]. Am J Obstet Gynecol, 1996, 175: 1195-1200. doi: 10.1016/S0002-9378(96)70027-3 |
[22]
|
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16: 170-199. doi: 10.6004/jnccn.2018.0006 |
[23]
|
Del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers[J]. Gynecol Oncol, 2017, 146: 427-435. doi: 10.1016/j.ygyno.2017.06.013 |
[24]
|
Jaakkola S, Pukkala E, K Lyytinen H, et al. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer[J]. Int J Cancer, 2012, 131: E537-E543. doi: 10.1002/ijc.27321 |
[25]
|
Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment[J]. Gynecol Oncol, 1987, 26: 169-177. doi: 10.1016/0090-8258(87)90270-8 |
[26]
|
Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors-Review of the Literature[J]. Pathol Oncol Res, 2020, 26: 63-78. doi: 10.1007/s12253-018-00569-x |
[27]
|
Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies[J]. Lancet, 2015, 385: 1835-1842. doi: 10.1016/S0140-6736(14)61687-1 |
[28]
|
Manson JE, Chlebowski RT, Stefanick ML, et al. Meno-pausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials[J]. JAMA, 2013, 310: 1353-1368. doi: 10.1001/jama.2013.278040 |
[29]
|
Rasmussen ELK, Hannibal CG, Dehlendorff C, et al. Parity, infertility, oral contraceptives, and hormone replace-ment therapy and the risk of ovarianserous borderline tumors: A nationwide case-control study[J]. Gynecol Oncol, 2017, 144: 571-576. doi: 10.1016/j.ygyno.2017.01.002 |
[30]
|
Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial[J]. Cancer, 1999, 86: 1013-1018. doi: 10.1002/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1 |
[31]
|
Eeles RA, Morden JP, Gore M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial[J]. J Clin Oncol, 2015, 33: 4138-4144. doi: 10.1200/JCO.2015.60.9719 |
[32]
|
Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis[J]. Menopause, 2016, 23: 335-342. doi: 10.1097/GME.0000000000000508 |
[33]
|
Kuhle CL, Kapoor E, Sood R, et al. Menopausal hormone therapy in cancer survivors: A narrative review of the literature[J]. Maturitas, 2016, 92: 86-96. doi: 10.1016/j.maturitas.2016.07.018 |
[34]
|
Biglia N, Bounous VE, Sgro LG, et al. Treatment of climacteric symptoms in survivors of gynaecological cancer[J]. Maturitas, 2015, 82: 296-298. doi: 10.1016/j.maturitas.2015.07.006 |
[35]
|
Lin KJ, Cheung WY, Lai JY, et al. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer[J]. Int J Cancer, 2012, 130: 419-430. doi: 10.1002/ijc.26026 |
[36]
|
Murphy N, Strickler HD, Stanczyk FZ, et al. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women[J]. J Natl Cancer Inst, 2015, 107: djv210. doi: 10.1093/jnci/djv210 |
[37]
|
Caiazza F, Ryan EJ, Doherty G, et al. Estrogen receptors and their implications in colorectal carcinogenesis[J]. Front Oncol, 2015, 5: 19. http://europepmc.org/abstract/med/25699240 |
[38]
|
Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy[J]. Int J Cancer, 1989, 44: 833-839. doi: 10.1002/ijc.2910440515 |
[39]
|
Montella M, D'Arena G, Crispo A, et al. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J]. Int J Endocrinol, 2015, 2015: 854530. |
[40]
|
Hassan MM, Botrus G, Abdel-Wahab R, et al. Estrogen Replacement Reduces Risk and Increases Survival Times of Women with Hepatocellular Carcinoma[J]. Clin Gastroenterol Hepatol, 2017, 15: 1791-1799. doi: 10.1016/j.cgh.2017.05.036 |
[41]
|
Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer[J]. Int J Mol Sci, 2017, 18: 1713. doi: 10.3390/ijms18081713 |
[42]
|
Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial[J]. J Natl Cancer Inst, 2010, 102: 1413-1421. doi: 10.1093/jnci/djq285 |
[43]
|
Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer[J]. J Clin Oncol, 2016, 24: 59-63. http://jjco.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=jco&resid=24/1/59 |
[44]
|
Li Q, Kopecky KJ, Mohan A, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia[J]. Clin Cancer Res, 1999, 5: 1077-1084. http://www.ncbi.nlm.nih.gov/pubmed/10353741 |
[45]
|
Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin's lymphoma in women[J]. J Clin Oncol, 2001, 19: 1381-1387. doi: 10.1200/JCO.2001.19.5.1381 |
[46]
|
Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors[J]. Blood, 2000, 95: 2059-2067. doi: 10.1182/blood.V95.6.2059 |
[47]
|
Yang X, Wang C, He X, et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases[J]. Climacteric, 2017, 20: 268-273. doi: 10.1080/13697137.2017.1309382 |
[48]
|
Tauchmanovà L, Selleri C, De Rosa G, et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review[J]. Menopause, 2007, 14: 320-330. doi: 10.1097/01.gme.0000232032.84788.8c |
[49]
|
Sturniolo G, Zafon C, Moleti M, et al. Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer[J]. Eur Thyroid J, 2016, 5: 224-230. doi: 10.1159/000452488 |
[50]
|
O'Shea T, Crowley RK, Farrell M, et al. Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia[J]. Endocrinol Diabetes Metab Case Rep, 2016, 2016: 16-0054. |
[51]
|
Pines A. Hormone therapy and brain tumors[J]. Climacteric, 2011, 14: 215-216. doi: 10.3109/13697137.2010.533615 |
[52]
|
Benson VS, Kirichek O, Beral V, et al. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis[J]. Int J Cancer, 2015, 136: 2369-2377. doi: 10.1002/ijc.29274 |
[53]
|
Shu X, Jiang Y, Wen T, et al. Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching[J]. Asia Pac J Clin Oncol, 2019, 15: e147-e153. doi: 10.1111/ajco.13138 |